Nová antivirotika v léčbě hepatitidy C
| Title in English | New antivirotics in the treatment of hepatitis C |
|---|---|
| Authors | |
| Year of publication | 2014 |
| Type | Article in Periodical |
| Magazine / Source | Praktické lékárenství |
| MU Faculty or unit | |
| Citation | |
| Field | Epidemiology, infectious diseases and clinical immunology |
| Keywords | hepatitis C; pegylated interferon; ribavirin; boceprevir; telaprevir; sofosbuvir; simeprevir |
| Description | Treatment of chronic hepatitis C is undergoing extraordinary changes in the past 3 years. Direct-Acting Antiviral Agents (DAAs) are gradually introducing into routine clinical practice either in combination with pegylated interferon and ribavirin, or in interferon-free regimes. Boceprevir and telaprevir have been approved in the Czech Republic since 2012. Sobosbuvir and simeprevir have been available in the United States since the end of 2013, as well. |